Definium Therapeutics is trading 4.12% down at $36.10 as rising Treasury yields pressure growth-oriented biotech stocks. - The 10-year Treasury yield surged to 5.14%, a 19-year high; Brent crude was above $100, and stronger business activity revived inflation and higher-for-longer interest-rate concerns. - No fresh company-specific negative announcement was identified on September 24, 2026; the decline is consistent with biotech weakness, with XBI down 2.04%. - Broader market pressure was led by the Nasdaq.